肿瘤防治研究2012，Vol.39Issue(5)：515-518,4.DOI:10.3971/j.issn.1000-8578.2012.05.006
EGFR-TKI治疗肺腺癌的疗效与血清肿瘤标志物的相关性
Correlations between EGFR Tyrosine Kinase Inhibitor and Serum Level of Tumor Marker in Lung Adenocarcinoma
潘金兵 1侯宇虹 2钱皓瑜1
作者信息
- 1. 450003郑州,河南省人民医院呼吸科
- 2. 郑州大学第一附属医院急诊科
- 折叠
摘要
Abstract
Objective To investigate the relationship between epidermal growth factor receptor tyrosine ki-nase inhibitorsC EGFR-TKI) treatment effects and serum tumor markers in lung adenocarcinoma. Methods Forty-eight patients with advanced lung adenocarcinoma were treated with EGFR-TKI. The clinical features, survival time and the level of serum tumor markers for the patients before and after treatment were retrospectively analyzed. Results After EGFR-TKI treatment,the RR was 58.2% and DCR was 65. 6% in lung adenocarcinoma; and median survival time was 13. 2 months. Responses correlated significantly with smoking history and level of CEA or CA19-9 in serum(P<0. 05). Patients with higher level of serum CEA and CA19-9 had higher disease control rate and longer survival (P<0. 05). Conclusion Serum CA19-9 or CEA level can predict the response of EGFR-TKI to lung adenocarcinoma.关键词
表皮生长因子受体酪氨酸激酶抑制剂/肺腺癌/肿瘤标志物Key words
Epidermal growth factor receptor tyrosine kinase inhibitor/ Lung adenocarcinoma/ Tumor markers
分类
医药卫生引用本文复制引用
潘金兵,侯宇虹,钱皓瑜..EGFR-TKI治疗肺腺癌的疗效与血清肿瘤标志物的相关性[J].肿瘤防治研究,2012,39(5):515-518,4.
